

# Clinical trials of sitagliptin monotherapy

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>sitagliptin monotherapy vs metformin</b>			
Aschner , 2010 [NCT00449930] n=528/522 follow-up: 24 weeks	once-daily sitagliptin 100 mg versus twice-daily metformin 1000 mg	treatment-naive patients with type 2 diabetes	double-blind
<b>sitagliptin monotherapy vs placebo</b>			
Aschner , 2006 [NCT00087516] n=NA follow-up: 24 weeks	sitagliptin 100 or 200 mg daily versus placebo	patients with type 2 diabetes	
Barzilai , 2011 [NCT00305604] n=NA follow-up: 24 weeks	once-daily sitagliptin (100 or 50 mg, depending on renal function) versus placebo	elderly patients with type 2 diabetes	double-blind US
Chan , 2008 n=65/26 follow-up: 12 weeks	sitagliptin versus placebo	patients with type 2 diabetes and chronic renal insufficiency	double-blind
Mohan , 2009 n=NA follow-up: 18 weeks	sitagliptin 100mg once daily monotherapy versus placebo	Chinese, Indian, and Korean patients with type 2 diabetes inadequately controlled by diet and exercise.	double-blind
Nonaka , 2008 [NCT00371007] n=NA follow-up:	sitagliptin 100 mg daily monotherapy versus placebo	Japanese patients with type 2 diabetes	double-blind
Raz , 2006 n=NA follow-up:	sitagliptin 100 mg (or 200 mg) daily versus placebo	patients with type 2 diabetes mellitus and inadequate glycaemic control	
<b>sitagliptin monotherapy vs voglibose</b>			
Iwamoto , 2010 n=NA follow-up: 12 weeks	sitagliptin 50 mg once daily monotherapy versus voglibose 0.2 mg thrice daily before meals	Japanese patients with type 2 diabetes	double-blind

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>

## References

### **Aschner, 2010:**

Aschner P, Katzeff HL, Guo H, Sunga S, Williams-Herman D, Kaufman KD, Goldstein BJ Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes. *Diabetes Obes Metab* 2010;12:252-61 [20070351] [10.1111/j.1463-1326.2009.01187.x](https://doi.org/10.1111/j.1463-1326.2009.01187.x)

### **Aschner, 2006:**

Aschner P, Kipnes MS, Lunceford JK, Sanchez M, Mickel C, Williams-Herman DE Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. *Diabetes Care* 2006;29:2632-7 [17130196] [10.2337/dc06-0703](https://doi.org/10.2337/dc06-0703)

### **Barzilai, 2011:**

Barzilai N, Guo H, Mahoney EM, Caporossi S, Golm GT, Langdon RB, Williams-Herman D, Kaufman KD, Amatruda JM, Goldstein BJ, Steinberg H Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. *Curr Med Res Opin* 2011;27:1049-58 [21428727] [10.1185/03007995.2011.568059](https://doi.org/10.1185/03007995.2011.568059)

### **Chan, 2008:**

Chan JC, Scott R, Arjona Ferreira JC, Sheng D, Gonzalez E, Davies MJ, Stein PP, Kaufman KD, Amatruda JM, Williams-Herman D Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. *Diabetes Obes Metab* 2008;10:545-55 [18518892] [10.1111/j.1463-1326.2008.00914.x](https://doi.org/10.1111/j.1463-1326.2008.00914.x)

### **Mohan , 2009:**

Mohan V, Yang W, Son HY, Xu L, Noble L, Langdon RB, Amatruda JM, Stein PP, Kaufman KD Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. *Diabetes Res Clin Pract* 2009;83:106-16 [19097665] [10.1016/j.diabres.2008.10.009](https://doi.org/10.1016/j.diabres.2008.10.009)

### **Nonaka, 2008:**

Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, Suzuki H, Hirayama Y, Ahmed T, Davies MJ, Stein PP Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. *Diabetes Res Clin Pract* 2008;79:291-8 [17933414] [10.1016/j.diabres.2007.08.021](https://doi.org/10.1016/j.diabres.2007.08.021)

### **Raz, 2006:**

Raz I, Hanefeld M, Xu L, Caria C, Williams-Herman D, Khatami H Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. *Diabetologia* 2006;49:2564-71 [17001471] [10.1007/s00125-006-0416-z](https://doi.org/10.1007/s00125-006-0416-z)

### **Iwamoto , 2010:**

Iwamoto Y, Tajima N, Kadowaki T, Nonaka K, Taniguchi T, Nishii M, Arjona Ferreira JC, Amatruda JM Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. *Diabetes Obes Metab* 2010;12:613-22 [20590736] [10.1111/j.1463-1326.2010.01197.x](https://doi.org/10.1111/j.1463-1326.2010.01197.x)

Entry terms: sitagliptin, sitagliptin, sitagliptin phosphate, Januvia, MK 0431, MK0431, MK-0431,